RA Capital Healthcare Fund LP 4
4 · Werewolf Therapeutics, Inc. · Filed Jun 22, 2026
Research Summary
AI-generated summary of this filing
Werewolf Therapeutics (HOWL) 10% Owner RA Capital Sells Shares
What Happened RA Capital Management, L.P. (a reporting 10% owner via affiliated funds) sold a total of 416,911 shares of Werewolf Therapeutics (HOWL) on June 17, 2026. The filing shows two disposal entries: 389,216 shares for $136,226 and 27,695 shares for $9,693, a combined proceeds total of $145,919. The reported weighted-average price was $0.35 per share (sales occurred at prices ranging $0.34–$0.39). These were sales (not purchases), which are often routine fund or liquidity transactions rather than a direct management signal.
Key Details
- Transaction date: June 17, 2026; Filing date: June 22, 2026 (filed 5 days after the trades).
- Reported price: weighted average $0.35; per-footnote range $0.34–$0.39 across multiple trades.
- Shares sold: 416,911 total (389,216 + 27,695); total proceeds ≈ $145,919.
- Shares owned after transaction: not specified in the public Form 4 provided.
- Footnotes: F1 notes weighted-average price and offers to provide breakdown by price; F2/F4 indicate holdings were held directly by RA Capital Healthcare Fund, L.P. and Nexus Fund II; F3 explains the adviser/fund structure and disclaimers of beneficial ownership.
- Transaction type: marked as "S" (sale) — open market or private sale.
Context This filing reflects activity by an institutional 10% owner (funds managed by RA Capital), not an individual officer or director. Institutional sales can reflect portfolio rebalancing, liquidity needs, or other fund-level decisions and do not necessarily indicate insider views on company prospects. No option exercises, awards, gifts, or 10b5-1 plans are disclosed in this filing.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-06-17$0.35/sh−389,216$136,226→ 4,268,448 total(indirect: See footnotes) - Sale
Common Stock
[F1][F3][F4]2026-06-17$0.35/sh−27,695$9,693→ 303,719 total(indirect: See footnotes)
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.34 to $0.39 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]Held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
- [F3]RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of the reported securities, except to the extent of their respective pecuniary interest therein.
- [F4]Held directly by Nexus Fund II.